Athenex, a Buffalo-based biotech, has begun site preparation for its $200 million manufacturing facility in Dunkirk, New York.
Land clearing at the site began recently, and construction is expected to begin later this summer with roof, exterior and glass likely to be up by the fourth quarter this year, Teresa Bair, an Athenex vice president, told the Observer.
The plant is scheduled to be fully operational by the first half of 2020 and will employee about 900 people, she said.
Athenex announced plans for the facility nearly two years ago when it signed an agreement with the U.S. unit of German construction company M+W. When completed, the plant will be about 320,000 square feet.
The company, which was founded in 2002 as Kinex, focuses on oncology drugs of which it has said it has about six major clinical-stage candidate compounds. Athenex is also working with the municipal government of Chongqing in China for the construction of a pair of drug manufacturing plants at Banan where it can produce high-potency oncology active pharmaceutical ingredients.